BioDebt: Wooing the Lower-Risk Investor
Executive Summary
Biotech companies suffer under a financing handicap: they can only attract high-risk equity investors. Now a few companies, albeit with products on the market or nearly so, are borrowing money and, along with interest, paying investors royalties on product sales. They're looking to tap into a group of investors with a lower appetite for risk but who require something more from unproven companies than just a standard interest rate.
You may also be interested in...
Terrorism's Impact on the Drug Industry
Terrorism has lowered investors' tolerance for risk. Investors aren't willing to accept as they have in the past the traditional uncertainties of biopharmaceutical investing. Instead, they are looking for companies that understand how to manage all risk, starting with technology and extending into partnering potential, the regulatory arena, and the marketplace. Beyond these visible dangers lies a subtle one: the societal risk posed by the drug industry's aggressive pricing strategies.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.